Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15592764 | 0.88 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL580695 | 0.77 | ALDH1A1 (0.38) | ARG1ARG2TSHRLMNAADRA1A | |
| SCHEMBL2200625 | 0.77 | ALDH1A1 (0.38) | ARG1ARG2TSHRLMNAADRA1A | |
| SCHEMBL9180645 | 0.75 | ALDH1A1 (0.37) | ARG1ARG2TSHRLMNA | |
| SCHEMBL9181624 | 0.73 | ALDH1A1 (0.35) | ARG1ARG2LMNA | |
| SCHEMBL9181588 | 0.73 | ALDH1A1 (0.35) | ARG1ARG2LMNA | |
| SCHEMBL9184201 | 0.73 | ALDH1A1 (0.35) | ARG1ARG2LMNA | |
| SCHEMBL9344562 | 0.73 | ALDH1A1 (0.35) | ARG1ARG2LMNA | |
| SCHEMBL3550645 | 0.73 | CYP4F2 (0.31) | — | |
| SCHEMBL3546760 | 0.73 | KDM4E (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | ARG1 1052/4885ARG2 485/4885TSHR 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.